Sign in

NCT07785882Not yet recruiting

Sarcoma and Intra-infusion Exercise for Better Outcomes

Sarcoma and Intra-infusion Exercise for Better Outcomes: The SEB-trial

Source: ClinicalTrials.gov · Last updated 25 Aug 2026

Brief summary (registry, in English)

The main goal of this clinical trial is to determine: 1) the safety and 2) feasibility of moderate-intensity, intra-infusion aerobic exercise in people receiving chemotherapy for non-resected sarcoma and 3) assess whether intra-infusion exercise acutely increases tumor perfusion. The trial aims to answer the following research questions: * Is intra-infusion aerobic exercise safe in people receiving chemotherapy for sarcoma? * Is intra-infusion aerobic exercise feasible in people receiving chemotherapy for sarcoma? * Does aerobic exercise induce acute increases in tumor perfusion? * In future work, which patient reported outcomes are relevant to explore in people receiving chemotherapy for sarcoma? Adverse event data and patient-reported quality-of-life outcomes will be compared to those of a historical control comprising patients who received chemotherapy for sarcoma within three years prior to study initiation. Participants will: * Participate in light- to moderate-intensity aerobic exercise during chemotherapy infusion (intra-infusion exercise) for the duration of their treatment protocol. * Exercise will follow a 15-minute exercise / 15-minute rest interval, totaling 30 minutes of exercise per hour of infusion. * Prior to initiating chemotherapy, undergo a single 15-minute exercise session. During peak exercise, a radioactive tracer will be injected intravenously followed by a single-photon emission computed tomography and computed tomography (SPECT /CT) scan to obtain images of tumor perfusion. A resting SPECT/CT scan will also be performed.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
16 (estimated)
First submitted
11 Aug 2026
Start date
1 Jan 2027
Primary completion date
31 Oct 2028
Lead sponsor
Kira Bloomquist
Diseases
Sarcoma
NCT number
NCT07785882

What you commit to

  • Study type: Interventional
  • Planned participants: 16
  • From 1 Jan 2027 to the primary completion date, 31 Oct 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Home-based chemotherapy

Lab values

  • Elevated risk for developing cardiac issues (left ventricular ejection fraction ≤50%) based on routine echocardiography

Other

  • Infusions lasting under one hour

Who the study is looking for

  • Initiating at least two series of chemotherapy for non-resected sarcoma at Clinic 6, Herlev Hospital, Denmark
  • Eastern Cooperative Oncology Group performance status of 0-2
  • No mental or physical disabilities precluding exercise
  • Approval by the treating oncologist
  • Able to read Danish
  • Willing to sign informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Department of Oncology, Herlev Hospital
Coordinator of this site? Confirm its status
HerlevDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.